PATENT CLAIM ANALYSIS

Application Number: 16178618
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["514", "017200"]

Abstract:
Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II α1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Claim (Index 5):
The method of  claim 1 , wherein the pharmaceutical composition is any one formulation selected from the group consisting of eye drops, injections, granules, tablets, pills, capsules, gels, syrups, suspensions, emulsions, drops and liquids.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 98.0
- Lexical Diversity: 1.25455
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14979511', '12709895', '15566034', '15569122', '11791425']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7922125522270591
- 35 USC 102 Novelty (BERT): 0.4833631982433847
- Combined Prediction Score: 0.7613276168286918
- Mean Citation Score: 199.70718
- Max Citation Score: 249.10124
- Similarity Product: 222.8063197983193

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test